🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "huge turning point" in the fight against superbug strains of the pathogen, according to researchers.

An International Health Concern

Cases of gonorrhoea are on the rise around the world, with data suggesting more than 82 million instances annually. Notably increased rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an important and timely development in the context of growing infection rates, increasing antimicrobial resistance and the highly restricted treatment choices presently on offer.”

Health officials are increasingly worried about the surge in antibiotic-resistant strains. The World Health Organization has listed it as a "critical concern". Recent surveillance revealed that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Treatment Options Secure Approval

One new antibiotic, also known as a brand name, was approved by the American regulatory agency in mid-December for use against gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Experts believe that targeted use of this new drug will help hinder the emergence of superbugs.

Gepotidacin, created by the drugmaker GlaxoSmithKline, also received approval in the same week. This medication, which is employed against UTIs, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin stemmed from a innovative non-profit model for medication research. The charitable organization GARDP collaborated with the drug firm its industry partner to see it through.

“This milestone signifies a huge turning point in the treatment of highly resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Clinical Trial Results and Global Access

Based on data released by a prominent scientific publication, zoliflodacin eradicated over nine in ten of genital gonorrhoea infections. This puts it on an comparable level with the existing first-line therapy, which combines two antibiotics. The research included nearly 1,000 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the rights to license and sell the drug in numerous low-income and middle-income countries.

Medical professionals on the front lines have voiced optimism. Having a single-dose, oral treatment such as this is described as a "game-changer" for gonorrhoea control. This is deemed vital to alleviate the strain of the infection for individuals and to halt the transmission of highly drug-resistant gonorrhoea worldwide.